	US 12,447,183 B2
	Bacterial strains, their compositions and their use for the treatment of gastrointestinal disorders
Andrea Biffi, Trezzano Rosa (IT); and Walter Fiore, Trezzano Rosa (IT)
Assigned to ALFASIGMA S.P.A., Bologna (IT)
Appl. No. 17/761,980
Filed by ALFASIGMA S.P.A., Bologna (IT)
PCT Filed Sep. 21, 2020, PCT No. PCT/IB2020/058769 § 371(c)(1), (2) Date Mar. 18, 2022, PCT Pub. No. WO2021/053636, PCT Pub. Date Mar. 25, 2021.
Claims priority of application No. 102019000016811 (IT), filed on Sep. 20, 2019.
Prior Publication US 2022/0339216 A1, Oct. 27, 2022
Int. Cl. A61K 35/745 (2015.01); A61K 35/747 (2015.01); A61P 1/00 (2006.01)

CPC A61K 35/745 (2013.01) [A61K 35/747 (2013.01); A61P 1/00 (2018.01)]

5 Claims

1. A method comprising administering as a medicament to a subject with irritable bowel syndrome (IBS) a composition comprising a mixture M comprising:

Bifidobacterium bifidum MIMBb23sg DSM 32708;

and at least one bacterial strain selected from the group consisting of:

Bifidobacterium breve BbIBSO1 DSM 33231;

Bifidobacterium breve BbIBS02 DSM 33232;

Bifidobacterium animalis subsp. lactis BlIBSO1 DSM 33233;

Lactobacillus plantarum LpIBSO1 DSM 33234;

or mixtures thereof;

said composition optionally further comprising at least one food or pharmaceutical grade additive and/or excipient.